文章核心观点 Levi & Korsinsky, LLP通知Zynex, Inc.投资者有关该公司的证券集体诉讼，指控被告存在证券欺诈行为，投资者可在规定时间申请成为首席原告，且参与无成本 [1][2][3] 案件详情 - 被告虚假陈述或隐瞒情况，包括产品发货超需求、虚增收入、虚假索赔受保险公司审查、可能面临不利后果及积极陈述误导等 [2] 后续安排 - 相关时间段内受损投资者需在2025年5月19日前申请成为首席原告，不担任也可分享赔偿 [3] 律所优势 - Levi & Korsinsky过去20年为股东获数亿美元赔偿，擅长复杂证券诉讼，有超70名员工，连续7年跻身美国证券诉讼律所前50 [4] 联系方式 - 律所信息：Levi & Korsinsky, LLP，地址为33 Whitehall Street, 17th Floor, New York, NY 10004，邮箱[email protected]，电话(212) 363 - 7500，传真(212) 363 - 7171，网址www.zlk.com [5]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, April 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP ...

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Zynex securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of ...

NEW YORK, April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=141948&from=4 CLASS PERIOD: March 13, 2023 to March 11, 2 ...

PHILADELPHIA, April 9, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired ZYNEX securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of the c ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-for ...

NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=140991&from=4CLASS PERIOD: March 13, 2023 to March 11, 202 ...

公司行为调查 - 律师事务所Faruqi & Faruqi正在调查Zynex公司潜在证券法违规行为 涉及2023年3月13日至2025年3月11日期间投资者损失超过7.5万美元的情况 [1][3] - 指控内容包括过度发货电极等产品人为抬高营收 向保险公司提交虚假索赔导致Tricare等机构审查 可能面临被移出保险网络及政府处罚等后果 [5] - 2024年6月4日STAT医疗期刊曝光公司"过量供应计划" 通过超量配送电极垫和电池向保险公司超额收费 导致部分保险公司终止合作 [6] 财务与股价影响 - 2024年第四季度财报显示收入"显著短缺" 主因是保险公司付款速度放缓 Tricare已暂停付款并审查历史索赔 [7] - 2024年6月4日股价单日下跌0.5美元(跌幅5%)至9.35美元 2025年3月12日因财报利空暴跌3.59美元(跌幅51.3%)至3.41美元 两次均伴随异常高成交量 [6][8] 法律程序进展 - 集体诉讼截止日期为2025年5月19日 法院将指定具有最大财务利益的适格投资者作为首席原告 [3][9] - 律师事务所自1995年成立以来已为投资者追回数亿美元赔偿 目前通过多种渠道征集Zynex相关行为证据 [4][10]

文章核心观点 - 公司通过旗舰设备NexWave提供无创、非成瘾性的家庭疼痛管理方案，以应对阿片类药物危机，销售副总裁阐述公司使命、产品特点及发展愿景 [1] 公司情况 - 销售副总裁Steve Fox有近20年销售和运营经验，涉足多个领域，因公司文化、使命和增长潜力加入 [3][4] - 公司核心是无创、非阿片类疼痛管理，约300名销售代表在美国向医疗服务提供者宣传家庭疼痛管理替代方案 [5] 产品情况 - 旗舰产品NexWave是三合一设备，包含TENS、IFC和NMES功能，适用于康复和疼痛管理，受医疗服务提供者欢迎 [6] 发展愿景 - 销售副总裁的工作是延续并扩大公司的增长，让更多医疗服务提供者了解公司，使公司家喻户晓 [7] - 目前公司主要聚焦美国市场，销售代表注重对医疗服务提供者的教育 [8] 公司文化 - 公司使命是提供家庭、无创、非成瘾性疼痛管理方案，这驱动着公司发展，所有销售代表都认同该使命 [9] 市场契合度 - 随着人口老龄化，更多人避免手术且需非阿片类疼痛管理方案，公司产品无创、非成瘾、易用，受老年群体欢迎 [10]

文章核心观点 Levi & Korsinsky, LLP 通知 Zynex, Inc. 投资者有关该公司的证券集体诉讼，指控被告证券欺诈，投资者可在规定时间申请成为首席原告，律所经验丰富 [1][2][3] 案件详情 - 被告虚假陈述或隐瞒公司产品发货超需求、虚增收入、虚假索赔遭保险公司审查、可能面临不利后果及相关积极陈述误导等情况 [2] 后续安排 - 相关时间段内受损的投资者需在 2025 年 5 月 19 日前申请成为首席原告，不担任首席原告也可参与赔偿分配 [3] 律所优势 - 过去 20 年为股东争取数亿美元赔偿，擅长复杂证券诉讼，有超 70 名员工，连续 7 年跻身美国证券诉讼律所前 50 [4] 联系方式 - 律所信息：Levi & Korsinsky, LLP，地址为 33 Whitehall Street, 17th Floor, New York, NY 10004，邮箱 [email protected]，电话 (212) 363 - 7500，传真 (212) 363 - 7171，网址 www.zlk.com [5] - 投资者可通过链接 https://zlk.com/pslra - 1/zynex - inc - lawsuit - submission - form?prid = 140697&wire = 4 获取信息，也可联系 Joseph E. Levi, Esq.，邮箱 [email protected]，电话 (212) 363 - 7500 [1]